Clinical trials of pegfilgrastim have been shown to have a favourable competence and safety profile for prophylactic usage in patients with cancer receiving chemotherapy and at risk of severe neutropenia and may be preferred by both physicians and patients over short-acting G-CSF due to enhanced adherence and a simple once-per-cycle subcutaneous injection (90–92). The gene discussed is CSF3; the disease is neutropenia.